These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25608124)

  • 21. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease.
    Goberman AM
    Med Sci Monit; 2005 Mar; 11(3):CR109-16. PubMed ID: 15735562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of levodopa on vocal function in Parkinson's disease.
    Sanabria J; Ruiz PG; Gutierrez R; Marquez F; Escobar P; Gentil M; Cenjor C
    Clin Neuropharmacol; 2001; 24(2):99-102. PubMed ID: 11307045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acoustic investigation of stress patterns in Parkinson's disease.
    Tykalova T; Rusz J; Cmejla R; Ruzickova H; Ruzicka E
    J Voice; 2014 Jan; 28(1):129.e1-129.e8. PubMed ID: 24094802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [F0 characteristics in Parkinsonian speech: Contrast between the effect of hypodopaminergy due to Parkinson's disease and that of the therapeutic delivery of L-Dopa].
    Ghio A; Robert D; Grigoli C; Mas M; Delooze C; Mercier C; Viallet F
    Rev Laryngol Otol Rhinol (Bord); 2014; 135(2):63-70. PubMed ID: 26521344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of vocal symptoms in Parkinson's disease: the Lee Silverman method].
    Dias AE; Limongi JC
    Arq Neuropsiquiatr; 2003 Mar; 61(1):61-6. PubMed ID: 12715021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Singing in groups for Parkinson's disease (SING-PD): a pilot study of group singing therapy for PD-related voice/speech disorders.
    Shih LC; Piel J; Warren A; Kraics L; Silver A; Vanderhorst V; Simon DK; Tarsy D
    Parkinsonism Relat Disord; 2012 Jun; 18(5):548-52. PubMed ID: 22436653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Speech defects of parkinsonian patients. Effects of levodopa therapy on speech intelligibility.
    Nakano KK; Zubick H; Tyler HR
    Neurology; 1973 Aug; 23(8):865-70. PubMed ID: 4737081
    [No Abstract]   [Full Text] [Related]  

  • 30. Levodopa therapeutics for Parkinson's disease: new developments.
    LeWitt PA
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prosodic expression and levodopa in Parkinson's disease.
    Behlau M
    Arq Neuropsiquiatr; 2013 Nov; 71(11):831-2. PubMed ID: 24394865
    [No Abstract]   [Full Text] [Related]  

  • 32. Swallowing improvement after levodopa treatment in idiopathic Parkinson's disease: lack of evidence.
    Melo A; Monteiro L
    Parkinsonism Relat Disord; 2013 Mar; 19(3):279-81. PubMed ID: 23231973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
    McColl CD; Reardon KA; Shiff M; Kempster PA
    Mov Disord; 2002 Nov; 17(6):1227-34. PubMed ID: 12465061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of levodopa treatment in the voice pattern of Parkinson's disease patients: a systematic review and meta-analysis.
    Pinho P; Monteiro L; Soares MFP; Tourinho L; Melo A; Nóbrega AC
    Codas; 2018 Oct; 30(5):e20170200. PubMed ID: 30304100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a single dose of standard levodopa on cardiac autonomic function in Parkinson's disease.
    Sriranjini SJ; Ganesan M; Datta K; Pal PK; Sathyaprabha TN
    Neurol India; 2011; 59(5):659-63. PubMed ID: 22019646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems.
    Plowman-Prine EK; Okun MS; Sapienza CM; Shrivastav R; Fernandez HH; Foote KD; Ellis C; Rodriguez AD; Burkhead LM; Rosenbek JC
    NeuroRehabilitation; 2009; 24(2):131-44. PubMed ID: 19339752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Micturition disturbances in Parkinson's disease. Clinical and urodynamic evaluation].
    Krygowska-Wajs A; Weglarz W; Szczudlik ZD
    Neurol Neurochir Pol; 2002; 36(1):25-32. PubMed ID: 12053613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
    Vidal EI; Fukushima FB; Valle AP; Villas Boas PJ
    J Am Geriatr Soc; 2013 Jan; 61(1):170-2. PubMed ID: 23311565
    [No Abstract]   [Full Text] [Related]  

  • 40. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.